NCCN Guidelines® Insights - Prostate Cancer, Version 1.2014
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.
Target Audience
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for prostate cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for prostate cancer
Available Credit
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician
Price
Required Hardware/software
To access this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for article and certificate viewing/printing